NCT01483924View on ClinicalTrials.gov

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

October 31, 2013

Conditions
Plaque Psoriasis
Interventions
DRUG

Apo805K1

Sequential parallel dose escalation.

Trial Locations (7)

75246

Menter Dermatology Research Institute, Dallas

77030

Center for Clinical Studies, Houston

77598

Center for Clinical Studies, Houston

84132

The University of Utah, Salt Lake City

90017

Axis Clinical Trials, Los Angeles

90036

Axis Clinical Trials, Los Angeles

H2K4L5

Innovaderm Research Inc., Montreal

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT01483924 - Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter